Precision BioSciences, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Juli Blanche
- Full Time Employees
- 108
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 302 East Pettigrew Street Durham NC United States of America 27701
- IPO Date
- Mar 28, 2019
- CIK
- 0001357874
- Website
- precisionbiosciences.com
- Similar Companies
- Business
- Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical-stage biotechnology company that develops in vivo gene editing therapies utilizing its proprietary ARCUS genome editing platform for precise DNA insertion, excision, elimination, and repair to address genetic and infectious diseases. The company offers a pipeline of product candidates including PBGENE-HBV, which targets chronic hepatitis B virus by eliminating covalently closed circular DNA and inactivating integrated HBV DNA; PBGENE-3243 for m.3243-associated mitochondrial disease; PBGENE-DMD, an in vivo therapy designed to restore near full-length dystrophin protein for up to 60% of Duchenne muscular dystrophy patients; PBGENE-PH1 for primary hyperoxaluria type 1; PBGENE-LIVER, PBGENE-CNS, and PBGENE-NVS programs; as well as the partnered iECURE-OTC program for ornithine transcarbamylase deficiency. ARCUS supports applications in rare genetic disorders, viral infections, and mitochondrial diseases, with delivery via viral and non-viral methods to diverse tissues. Founded in 2006 and headquartered in Durham, North Carolina, Precision BioSciences operates primarily in the United States with global clinical activities, including approved INDs and CTAs in the US, UK, and Australia for its lead programs. The company targets patients with incurable genetic conditions and has partnerships with iECURE for the OTC program, Novartis, and others, while previously licensing its allogeneic CAR-T program to Imugene in 2023. Recent developments include the return of three ARCUS programs from Prevail Therapeutics (an Eli Lilly subsidiary) in April 2024 after a productive collaboration that advanced proof-of-concept for gene excision and insertion; preclinical advancements and presentations for PBGENE-DMD at ASGCT 2025 showing durable dystrophin restoration and muscle improvements; Phase 1 data from the ELIMINATE-B trial for PBGENE-HBV demonstrating antiviral activity and safety; a $75 million public offering of common stock, pre-funded warrants, and warrants in late 2025; and progression toward IND/CTA submissions for PBGENE-PMM in 2025, with a cash runway into the second half of 2026.
Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026
Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026
Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study
Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026
Precision BioSciences, Inc. (DTIL) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries
Should You Buy Precision BioSciences (DTIL) After Golden Cross?
Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference
Precision BioSciences, Inc. (DTIL) Shareholder/Analyst Call Transcript
Precision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue Estimates
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program
Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026